<DOC>
	<DOCNO>NCT02625740</DOCNO>
	<brief_summary>The PACUS Trial single center , single blind , randomize trial design evaluate safety efficacy intravascular percutaneous catheter-delivered ultrasound energy improve local Paclitaxel delivery effect critical limb ischemia patient due femoral-popliteal artery disease .</brief_summary>
	<brief_title>Ultrasound Enhance Paclitaxel Uptake Critical Limb Ischemia : PACUS Trial</brief_title>
	<detailed_description>Study design The PACUS Trial single center , single blind , randomize trial design evaluate safety efficacy intravascular percutaneous catheter-delivered high intensity , low-frequency ultrasound utilize CardioProlific Genesis™ System improve local paclitaxel delivery effect patient CLI due femoral-popliteal calcific lesion occlusion . The protocol approve Local Review Boards Institutional Ethics Committee . All patient provide write informed consent enrollment . The trial conduct accordance declaration Helsinki . Randomization Randomization occur successful cross pre-dilatation target lesion standard percutaneous angioplasty balloon without sub-intimal approach and/or flow limit dissection . Patients enrol successful angiographic control perform PTA pre-dilatation . Subjects randomly assign computer-generated random sequence ( 2 block 1:1 ratio ) . Randomization do advance patient without stratification . The patient physician involve follow-up control blind treatment assignment completion 6 month follow-up evaluation . Operators blind due difference treatment protocol . Twenty eight ( 28 ) patient treat intravascular percutaneous catheter-delivered high intensity , low-frequency ultrasound local Paclitaxel delivery temporarily blood flow occlusion create distal occlusion balloon ( Study Group ) , twenty eight ( 28 ) patient treat drug elute balloon conventional method ( Control Group ) .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Rutherford category ≥4 femoralpopliteal lesion ≥10cm successful intraluminal recanalization without need stent obtain satisfactory angiographic result least one patent knee vessel patient older 18 year Rutherford category &lt; 4 pregnancy know allergy study medication material need subintimal approach perform recanalization target vessel stent release</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>